What is the 13F Pro Quality Score for HOWL?

13F Pro ranks Werewolf Therapeutics, Inc. (HOWL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View HOWL's current score at https://13fpro.ai/research/HOWL (free sign-up required for the full ranking).

Where does 13F Pro source HOWL data?

All Werewolf Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Werewolf Therapeutics, Inc. files with the SEC under CIK 1785530. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is HOWL in?

Werewolf Therapeutics, Inc. (HOWL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is HOWL research updated on 13F Pro?

HOWL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Werewolf Therapeutics, Inc.(HOWL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1785530 HOWL stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

HOWL Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Werewolf Therapeutics, Inc. (HOWL), a Healthcare sector company. HOWL is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Werewolf Therapeutics, Inc. reports net income of $-13.5M, free cash flow of $-10.6M. Top institutional holders of HOWL by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., VANGUARD CAPITAL MANAGEMENT, MPM BioImpact, based on the most recent SEC filings. HOWL trades on the Nasdaq exchange and files with the SEC under CIK 1785530. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HOWL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Werewolf Therapeutics, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-13.5M

Free Cash Flow

Q1 2026

$-10.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+13.7% YoY

$-60.8MFY 2025

FY22 $-53.8MFY23 $-37.4MFY24 $-70.5MFY25 $-60.8M

Operating Income

+17.6% YoY

$-60.7MFY 2025

FY22 $-56.1MFY23 $-40.5MFY24 $-73.6MFY25 $-60.7M

EPS (Diluted)

+18.4% YoY

$-1.33FY 2025

FY22 $-1.86FY23 $-1.05FY24 $-1.63FY25 $-1.33

Total Assets

-45.3% YoY

$69.4MFY 2025

FY22 $160.2MFY23 $174.8MFY24 $126.9MFY25 $69.4M

Total Debt

+0.0% YoY

$32.1MFY 2025

FY22 —FY23 $40.0MFY24 $32.1MFY25 $32.1M

Op. Cash Flow

-7.3% YoY

$-60.3MFY 2025

FY22 $-40.6MFY23 $-32.6MFY24 $-56.2MFY25 $-60.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Income	$-60.8M +13.7%	$-70.5M -88.7%	$-37.4M +30.6%	$-53.8M -7.7%	$-50.0M -232.3%	$-15.0M
Operating Income	$-60.7M +17.6%	$-73.6M -81.7%	$-40.5M +27.7%	$-56.1M -11.9%	$-50.1M -123.6%	$-22.4M
EPS (Diluted)	$-1.33 +18.4%	$-1.63 -55.2%	$-1.05 +43.5%	$-1.86 +83.0%	$-10.94 +61.0%	$-28.08
Total Assets	$69.4M -45.3%	$126.9M -27.4%	$174.8M +9.1%	$160.2M -10.6%	$179.3M +85.9%	$96.4M
Total Debt	$32.1M +0.0%	$32.1M -19.8%	$40.0M	—	—	—
Operating Cash Flow	$-60.3M -7.3%	$-56.2M -72.3%	$-32.6M +19.7%	$-40.6M +5.3%	$-42.9M -130.2%	$-18.6M

AI Insight: HOWL Financial Trends

Werewolf is burning cash toward insolvency: equity halved to $12M in 18 months with no revenue and persistent operating losses.

• Net income improved from -$20M in Q4 2024 to -$8M in Q4 2025, then widened to -$14M in Q1 2026.

• Operating cash flow remains deeply negative, ranging -$11M to -$19M per quarter with no sign of stabilization.

• Equity eroded 88% from $104M (Q2 2024) to $12M (Q1 2026) while debt held flat at $32M.

⚠ Equity of $12M covers only 9 months of current burn rate; imminent dilution or financing crisis likely.

⚠ Debt-to-equity ratio inverted to 2.7x; company is technically insolvent on book basis.

⚠ No revenue reported across any quarter; clinical-stage company with no clear monetization timeline visible.

AI Insight: HOWL Ratio Trends

Werewolf Therapeutics is hemorrhaging capital with deepening losses and leverage nearly doubling since mid-2024, signaling an unsustainable burn trajectory.

• ROA deteriorated from -44.9% in Q2 2024 to -93.3% in Q1 2026, reflecting accelerating net losses relative to asset base.

• Debt-to-equity ratio surged from 0.31 in Q2 2024 to 2.63 in TTM 2026, indicating aggressive leverage accumulation to fund operations.

• ROE fell from -66.3% in Q2 2024 to -173.5% in Q2 2025 before partial recovery to -135.2% in Q4 2025, showing volatile but persistently negative returns.

⚠ Q4 2025 ROA improved sharply to -48.3% from -82.2% in Q3 2025—monitor whether this signals operational stabilization or reflects one-off adjustments.

⚠ Lack of positive margins (OpMargin, NPM all missing) indicates pre-revenue or cash-burn stage; runway and financing capacity are critical.

Get alerted when HOWL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Werewolf Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of HOWL

RA CAPITAL MANAGEMENT, L.P.
$5.6M6,681,307 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.0M1,217,976 sh
MPM BioImpact LLC
$1.0M1,208,810 sh
Lynx1 Capital Management LP
$547.7K657,786 sh
SPHERA FUNDS MANAGEMENT LTD.
$521.9K626,810 sh
DC Funds, LP
$490.5K589,102 sh
Squadron Capital Management LLC
$469.2K563,535 sh
RENAISSANCE TECHNOLOGIES LLC
$429.8K516,218 sh
GEODE CAPITAL MANAGEMENT, LLC
$324.4K389,487 sh
BANK OF AMERICA CORP /DE/
$220.1K264,583 sh

Fund	Value	Shares
RA CAPITAL MANAGEMENT, L.P.	$5.6M	6,681,307
VANGUARD CAPITAL MANAGEMENT LLC	$1.0M	1,217,976
MPM BioImpact LLC	$1.0M	1,208,810
Lynx1 Capital Management LP	$547.7K	657,786
SPHERA FUNDS MANAGEMENT LTD.	$521.9K	626,810
DC Funds, LP	$490.5K	589,102
Squadron Capital Management LLC	$469.2K	563,535
RENAISSANCE TECHNOLOGIES LLC	$429.8K	516,218
GEODE CAPITAL MANAGEMENT, LLC	$324.4K	389,487
BANK OF AMERICA CORP /DE/	$220.1K	264,583

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put HOWL on your watchlist

Track score changes the day Werewolf Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is HOWL a good stock to buy?

13F Pro's AI-powered analysis of Werewolf Therapeutics, Inc. (HOWL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HOWL are available on the HOWL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own HOWL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HOWL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Werewolf Therapeutics, Inc.'s investment landscape.